Response document for MHRA public consultation on the proposal to make Dovonex Psoriasis Ointment available in Pharmacies

Ref: ARM95

Your details
Name: DR PAMELA MCHENRY
Position (if applicable): CONSULTANT DERMATOLOGIST; CHAIR, THERAPY & GUIDELINES SUB-COMMITTEE
Organisation (if applicable): BRITISH ASSOCIATION OF DERMATOLOGISTS
Email: clinicalstandards@bad.org.uk

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?
Yes ☑ No ☐ Not sure ☐

Please provide any comments or evidence to support your response:

1. There will be an increasing drive for those who can pay to buy their own medicaments – without prescription. Dovonex is generally safe and safer than some existing P / GSL medicines; the main problem is local irritation and hypercalcaemia if excess applied. It will be helpful for patient to access the treatment if unable to refill a prescription from GP.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

1. There is potential for confusion if prescribed use is twice a day and non-prescribed use stated to only be once a day. Ideally, they should be harmonised. Many dermatologists prescribe Dovonex in conjunction with UVB therapy – though not applied just before treatment. Suggesting that the combination can increase skin cancer risk may raise patient anxiety.

2. Not for the face, genitals, flexural skin or children.

3. Do you have any other comments on the reclassification?

1. Dovonex is a safe treatment and we are keen to support its reclassification so that it may be available over the counter. We hope that the instructions will make it clear that it should be applied thickly.
2. Apply generously. May cause mild irritation which should not limit treatment
3. Max amount that can be used in a week
4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes □ Partially* □ No ✔

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by 20 April 2017. Contributions received after that date cannot be included in the exercise.